Literature DB >> 18724072

Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution.

Inmaculada Hernández-Muñoz1, Anouchka Skoudy, Francisco X Real, Pilar Navarro.   

Abstract

Pancreatic cancer has a very poor prognosis, in part due to its diagnosis at late stages of the disease and to limited response to chemotherapy and radiotherapy. The vast majority of pancreatic cancers are classified as pancreatic ductal adenocarcinomas (PDACs). Despite advances in knowledge on the cellular origin of PDAC or the involvement of signal transduction pathways therein, many questions remain unanswered. In this review, we summarize recent findings and current hypotheses regarding these two questions. Since pancreatitis is a risk factor for human PDAC, and the latter proceeds with an intense fibrotic reaction, we also analyze the role of the stroma in PDAC progression. An improved understanding of these key aspects for PDAC ontogeny will open new avenues for tumor prevention, early detection, and improved therapy. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18724072     DOI: 10.1159/000151537

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  13 in total

Review 1.  Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc.

Authors:  Anouchka Skoudy; Inmaculada Hernández-Muñoz; Pilar Navarro
Journal:  J Gastrointest Cancer       Date:  2011-06

Review 2.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications.

Authors:  Mert Erkan; Simone Hausmann; Christoph W Michalski; Alexander A Fingerle; Martin Dobritz; Jörg Kleeff; Helmut Friess
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-19       Impact factor: 46.802

3.  Oncogenic Ras/Src cooperativity in pancreatic neoplasia.

Authors:  D J Shields; E A Murphy; J S Desgrosellier; A Mielgo; S K M Lau; L A Barnes; J Lesperance; M Huang; C Schmedt; D Tarin; A M Lowy; D A Cheresh
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

Review 4.  Metabolism and epigenetics of pancreatic cancer stem cells.

Authors:  M Perusina Lanfranca; J K Thompson; F Bednar; C Halbrook; C Lyssiotis; B Levi; T L Frankel
Journal:  Semin Cancer Biol       Date:  2018-09-28       Impact factor: 15.707

5.  RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia.

Authors:  David J Shields; Sherry Niessen; Eric A Murphy; Ainhoa Mielgo; Jay S Desgrosellier; Steven K M Lau; Leo A Barnes; Jacqueline Lesperance; Michael Bouvet; David Tarin; Benjamin F Cravatt; David A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

Review 6.  Therapeutic antibodies for the treatment of pancreatic cancer.

Authors:  Patrick Chames; Brigitte Kerfelec; Daniel Baty
Journal:  ScientificWorldJournal       Date:  2010-06-15

7.  Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells.

Authors:  Hanieh Jafary; Shahin Ahmadian; Masoud Soleimani
Journal:  Mol Biol Rep       Date:  2014-03-05       Impact factor: 2.316

8.  FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours.

Authors:  Ibane Abasolo; Judit Pujal; Rosa M Rabanal; Anna Serafin; Pilar Navarro; Olga Millán; Francisco X Real
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-28       Impact factor: 9.236

9.  The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1.

Authors:  Geeske Genrich; Marcus Kruppa; Lennart Lenk; Ole Helm; Anna Broich; Sandra Freitag-Wolf; Christoph Röcken; Bence Sipos; Heiner Schäfer; Susanne Sebens
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

10.  Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER.

Authors:  Véronique Gigoux; Daniel Fourmy
Journal:  Front Endocrinol (Lausanne)       Date:  2013-04-29       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.